IQ-AI Ltd
("IQ-AI" or the
"Company")
Board
Changes
IQ-AI Appoints Renowned Brain
Tumor Champion to Board of Directors
IQ-AI Ltd (LSE: IQAI) is pleased to
announce the appointment of Dr. Al Musella, MD, as a Non-Execuitve
Director. Dr. Musella brings almost three decades of experience as
founder and president of the Musella Foundation for Brain Tumor
Research and Information, Inc.
Dr. Musella formed the first online
support group for brain tumor patients in 1993, which has since
evolved into the compreshensive resource website,
virtualtrials.org.
Under his leadership, the Musella Foundation has made many
significant contributions to the brain tumor community including
funding novel research, advocating for the approval of new
treatments, and helping patients access needed treatments with
financial support.
Dr Musella has issued more than
$19.3 million in brain tumor research grants and co-payment
assistance grants to help patients access needed treatments. He
also advocated for FDA and Medicare approval for Optune, Temodar,
Gliadel, Gleolan, Avastin and many other treatments. His
current efforts include lobbying for the "Promising Pathway Act,"
legislation that accelerates the clinical trial approval process in
order to move new drugs to market more efficiently.
"We are pleased to welcome Dr.
Musella to our Board of Directors," said Trevor Brown, CEO of
IQ-AI. "His extensive network and experience will be invaluable as
we forge ahead in the development of oral gallium maltolate and
build upon our core imaging business".
Dr. Musella commented, "I am honored
to join IQ-AI and the Imaging Biometrics team, and I look forward
to contributing to their efforts of helping brain tumor patients
and the clinicians who support them".
No information is required to be
disclosed pursuant to paragraph 9.6.13R of the Listing
Rules.
As part of these Board
Changes, Vinod Kaushal will step down as non-executive director
with immediate effect.
--ENDS-
The Directors of the Company accept
responsibility for the contents of this announcement.
For further information, please
contact:
|
IQ-AI Ltd
Trevor Brown/Vinod Kaushal/Brett
Skelly/Michael Schmainda
Tel: 020 7469 0930
|
|
Peterhouse Capital Limited (Financial Adviser and Broker)
Tel: 020 7220 9797
|
About Imaging Biometrics® LLC: IB is a wholly owned
subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering
quantitative imaging platforms and therapeutics that transform how
clinicians diagnose and treat patients more efficiently and
effectively. For more information about Imaging Biometrics, visit
the company's website at www.imagingbiometrics.com. Follow
IB on Twitter, @IQAI_IB.
